Clinical trial
Disposition of [14C]-Tirzepatide Following Subcutaneous Administration in Healthy Male Subjects
NCT04311424 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Disposition of [14C]-Tirzepatide Following Subcutaneous Administration in Healthy Male Subjects
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 28, 2020
- Completion date
- October 2, 2020
- Enrollment
- 6 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
healthy